Natalizumab

Drug Levels and Effects:




Summary of Use during Lactation:


There are no data on the use of natalizumab during breastfeeding. In a survey of women neurologists in the United States and Canada, 147 responded. Of these, 13% stated that they discourage breastfeeding with any immunomodulatory drug for their patient with multiple sclerosis, and 48% stated that they leave the decision on breastfeeding with interferon beta up to the patient.[1]


Drug Levels:


Maternal Levels.

Relevant published information was not found as of the revision date.

Infant Levels.

Relevant published information was not found as of the revision date.


Effects in Breastfed Infants:


Relevant published information was not found as of the revision date.


Possible Effects on Lactation:


Relevant published information was not found as of the revision date.


Alternate Drugs to Consider:


(Inflammatory Bowel Disease) Budesonide,Infliximab,Mesalamine,Prednisone,(Multiple Sclerosis) Glatiramer Acetate,Interferon beta


References:


1. Coyle PK, Christie S, Fodor P et al. Women Neurologists MS Initiative. Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler. 2004;10:582-8. PMID:15471377



Substance Identification:




Substance Name:

Natalizumab

CAS Registry Number:

189261-10-7

Drug Class:


  • Antibodies, Monoclonal, Humanized

  • Anti-Inflammatory Agents


  • Administrative Information:




    LactMed Record Number:


    716


    Last Revision Date:


    Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.